News >

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

Jason Harris
Published: Thursday, Oct 26, 2017

Dr. Sandra Horning
Sandra Horning, MD
The FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer, according to Genentech, the manufacturer of the angiogenesis inhibitor.

In both trials, the bevacizumab-containing regimens resulted in superior objective response. The ORR with bevacizumab was 78% in both studies compared with 56% in GOG-0213 and 57% in OCEANS for the chemotherapy arms.

References

  1. FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer. Genentech. http://bit.ly/2i548hf. Accessed October 26, 2017.
  2. FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer. Genentech. http://bit.ly/2z9buev. Accessed October 26, 2017.
  3. FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer. Genentech. http://bit.ly/2h2DQeB. Accessed October 26, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x